Pfizer Czech Republic made a net profit of CZK 134 mil under revenues of CZK 4,947 mil in 2014, down -7.25% and -8.51%, respectively, when compared to the last year. This translates into a net margin of 2.70%.
Historically, the firm’s net profit reached an all time high of CZK 272 mil in 2008 and an all time low of CZK -263 mil in 2002. Since 2009, the firm's net profit has increased -12.4% or -2.61% a year on average.
On the operating level, EBITDA reached CZK 172 mil, up -0.368% when compared to the previous year. Over the last five years, company's EBITDA has grown -6.21% a year on average.
As far as Pfizer Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 2.17% and 6.07%, respectively in 2014, Bayer Czech Republic generated margins of 2.64% and 3.53% and Amgen Czech Republic's profit margin reached 6.36% on the net and 8.55% on the EBITDA level in 2014.